Astellas scores FDA approval for life-threatening fungus-fighter

The FDA offers incentives for developing products that target life-threatening infections, and Astellas just became the latest drugmaker to take advantage. On Friday, the Japanese pharma bagged U.S. regulatory approval for Cresemba, an oral and injected antifungal that fights two rare but dangerous infections. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.